Background: Psoriasis is recognized as a systemic inflammatory disease that is characterized by metabolic syndrome. The MTHFR C677T gene is significant in psoriasis. Objectives: We are seeking to determine the prevalence of the MTHFR C677T genotype among plaque psoriasis patients and its correlation with clinical and subclinical characteristics at Can Tho Dermatology Hospital. Materials and Methods: From 2021 to 2023, 50 patients with plaque psoriasis who were treated at Can Tho Hospital of Dermato-Venereology participated in a descriptive cross-sectional study. Results: The percentage of males was 55.7%. The mean age was 46.60±14.77 years. The <40 years old group constituted 67.1% of the total. Disease had an average duration of 12.96±10.69 years. The symptom of stinging was prevalent (85.7%). Trunk (77.1%), cranium and extremities (75.7%), and nails (62.9%) were the most common sites of injury. The prevalence of metabolic syndrome was 47.1%. Plaque psoriasis patients with the MTHFR C677T C/T phenotype accounted for 48% and there were no cases with the T/T phenotype. When comparing patients with plaque psoriasis with the MTHFR C677T C/T phenotype with the group of the C/C phenotype, people carrying the T allele had a longer disease duration (13.83±10.45 and 8.27 ±5.71 years), more fold injuries (37.5% and 11.5%), a higher fasting blood glucose concentration (5.92±1.16 and 8.15±4.13), and a higher rate of metabolic syndrome (72.7% and 31.8%). Conclusions: MTHFR C677T C/T genotype plaque psoriasis patients had a longer illness duration, more lesions in the folds, and a greater risk of hyperglycemia and metabolic syndrome than C/C genotype carriers.